Article Details

Cancer Imunotherapy Developer Armo BioSciences Files for Up-to-$86.25M IPO

Retrieved on: 2018-01-01 22:48:45

Tags for this article:

Click the tags to see associated articles and topics

Cancer Imunotherapy Developer Armo BioSciences Files for Up-to-$86.25M IPO. View article details on hiswai:

Excerpt

<div>... Capital, Sequoia Capital, Quan Capital, and RTW Investments; as well as existing investors Kleiner Perkins (KP), OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments, GV (formerly <b>Google Ventures</b>), Celgene, and certain private investment funds advised by Clough Capital Partner.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up